Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px
Document › Details

Synaffix B.V.. (2/18/14). "Press Release: Synaffix Raises Series A Financing". The Netherlands.

Organisations Organisation Synaffix B.V.
  Organisation 2 MS Ventures (Merck Serono Ventures)
  Today Merck Ventures B.V. (M Ventures, MV)
  Group Merck (DE) (Group)
Products Product antibody-drug conjugates (ADC) technology
  Product 2 venture capital
Index terms Index term Synaffix–SEVERAL: investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital
  Index term 2 Synaffix–Aravis: investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital
     


SynAffix B.V., a protein engineering company focusing on the creation of next-generation Antibody-Drug Conjugates (ADCs), today announced the completion of its Series A investment round. Investors in the round are Aravis SA (Switzerland), BioGeneration Ventures (the Netherlands), MS Ventures, the corporate venture capital fund of Merck Serono and BOM Capital (the Netherlands).

   
Record changed: 2019-04-15

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Synaffix B.V.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top